A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013.
   Google Scholar
• Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.
   PubMed Web of Science ®Google Scholar
• Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990–6.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111–6.
   PubMed Web of Science ®Google Scholar
• Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Jr., Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005;294:1233–9.
   PubMed Web of Science ®Google Scholar
• Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008;71:330–7.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000;55:241–9.
   PubMed Web of Science ®Google Scholar
• Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes. Radiat Oncol 2011;6:3.
   PubMed Web of Science ®Google Scholar
• Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years. Radiat Oncol 2013;8:118.
   PubMed Web of Science ®Google Scholar
• King CR, Brooks JD, Gill H, Presti JC, Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;82:877–82.
   PubMed Web of Science ®Google Scholar
• McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: Preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012;118:3681–90.
   PubMed Web of Science ®Google Scholar
• Dasu A, Toma-Dasu I. Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncol 2012;51:963–74.
   PubMed Web of Science ®Google Scholar
• Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 2012;82:e17–24.
   PubMedGoogle Scholar
• Proust-Lima C, Taylor JM, Secher S, Sandler H, Kestin L, Pickles T, et al. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 2011;79:195–201.
   PubMed Web of Science ®Google Scholar
• Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience. Radiat Oncol 2013;8:58.
   PubMed Web of Science ®Google Scholar
• Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int J Radiat Oncol Biol Phys 2001;49:61–9.
   PubMed Web of Science ®Google Scholar
• Mendenhall NP, Hoppe BS, Morris CG, Nichols RC, Mendenhall WM, Su Z, et al. Five-year outcomes of proton therapy in localized prostate cancer on 3 prospective trials for low-, intermediate-, and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2013;87:S155.
   Google Scholar
• Lei S, Piel N, Oermann EK, Chen V, Ju AW, Dahal KN, et al. Six-dimensional correction of intra-fractional prostate motion with CyberKnife stereotactic body radiation therapy. Front Oncol 2011;1:48.
   PubMedGoogle Scholar
• Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic-function. Int J Radiat Oncol 1991;21:123–35.
   PubMed Web of Science ®Google Scholar
• Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method. Int J Radiat Oncol Biol Phys 1989;16:1623–30.
   PubMed Web of Science ®Google Scholar
• Kutcher GJ, Burman C, Brewster L, Goitein M, Mohan R. Histogram reduction method for calculating complication probabilities for 3-dimensional treatment planning evaluations. Int J Radiat Oncol 1991;21:137–46.
   PubMed Web of Science ®Google Scholar
• Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 1985;8:S13–9.
   PubMedGoogle Scholar
• Moiseenko V, Battista J, Van Dyk J. Normal tissue complication probabilities: Dependence on choice of biological model and dose-volume histogram reduction scheme. Int J Radiat Oncol 2000;46:983–93.
   PubMed Web of Science ®Google Scholar
• Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl): S123–9.
   PubMed Web of Science ®Google Scholar
• American Society for Radiation Oncology (ASTRO) Model Policy on Steretoactic Body Radiotherapy. 2013. [cited 2014 Jul 29].
   Google Scholar
• Kim YJ, Cho KH, Pyo HR, Lee KH, Moon SH, Kim TH, et al. A phase II study of hypofractionated proton therapy for prostate cancer. Acta Oncol 2013;52:477–85.
   PubMed Web of Science ®Google Scholar
• Vargas C, Fryer A, Mahajan C, Indelicato D, Horne D, Chellini A, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:744–51.
   PubMed Web of Science ®Google Scholar
• Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: A treatment planning comparison. Int J Radiat Oncol Biol Phys 2007;69:444–53.
   PubMed Web of Science ®Google Scholar
• Litzenberg DW, Balter JM, Hadley SW, Sandler HM, Willoughby TR, Kupelian PA, et al. Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:548–53.
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Langen KM, Willoughby TR, Zeidan OA, Meeks SL. Image-guided radiotherapy for localized prostate cancer: Treating a moving target. Semin Radiat Oncol 2008;18:58–66.
   PubMed Web of Science ®Google Scholar
• Dawson LA, Mah K, Franssen E, Morton G. Target position variability throughout prostate radiotherapy. Int J Radiat Oncol Biol Phys 1998;42:1155–61.
   PubMed Web of Science ®Google Scholar
• Crook JM, Raymond Y, Salhani D, Yang H, Esche B. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 1995;37:35–42.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Manola J, Loffredo M, Lopes L, Nissen K, O’Farrell DA, et al. A practical method to achieve prostate gland immobilization and target verification for daily treatment. Int J Radiat Oncol Biol Phys 2001;51:1431–6.
   PubMed Web of Science ®Google Scholar
• Sanghani MV, Ching J, Schultz D, Cormack R, Loffredo M, McMahon E, et al. Impact on rectal dose from the use of a prostate immobilization and rectal localization device for patients receiving dose escalated 3D conformal radiation therapy. Urol Oncol 2004;22:165–8.
   PubMed Web of Science ®Google Scholar
• Teh BS, McGary JE, Dong L, Mai WY, Carpenter LS, Lu HH, et al. The use of rectal balloon during the delivery of intensity modulated radiotherapy (IMRT) for prostate cancer: More than just a prostate gland immobilization device? Cancer J 2002;8:476–83.
   PubMed Web of Science ®Google Scholar
• Vargas C, Mahajan C, Fryer A, Indelicato D, Henderson RH, McKenzie C, et al. Rectal dose-volume differences using proton radiotherapy and a rectal balloon or water alone for the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 2007;69:1110–6.
   PubMed Web of Science ®Google Scholar
• MacDonald SM, Trofimov A, Safai S, Adams J, Fullerton B, Ebb D, et al. Proton radiotherapy for pediatric central nervous system germ cell tumors: Early clinical outcomes. Int J Radiat Oncol Biol Phys 2011;79:121–9.
   PubMed Web of Science ®Google Scholar
• Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: A dosimetric study. Int J Radiat Oncol Biol Phys 2011;81: 1336–42.
   PubMed Web of Science ®Google Scholar
• Paganetti H, van Luijk P. Biological considerations when comparing proton therapy with photon therapy. Semin Radiat Oncol 2013;23:77–87.
   PubMed Web of Science ®Google Scholar
• Gerweck LE, Kozin SV. Relative biological effectiveness of proton beams in clinical therapy. Radiother Oncol 1999; 50:135–42.
   PubMed Web of Science ®Google Scholar